Abstract
Lenalidomide Administered for the Initial Treatment of Chronic Lymphocytic Leukemia (CLL) Patients- In Vivo Modulation of the Leukemia Cell Surface Phenotype and Association with Tumor Flare Reaction (TFR).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have